Paper
Bromophenols from Symphyocladia latiuscula Target Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases.
Published Feb 3, 2020 · P. Paudel, S. E. Park, S. Seong
Journal of agricultural and food chemistry
18
Citations
1
Influential Citations
Abstract
Progressive degeneration of dopaminergic neurons in the substantia nigra is the characteristic feature of Parkinson's disease (PD) and the severity accelerates with aging. Therefore, improving dopamine level or dopamine receptor signaling is a standard approach for PD treatment. Herein, our results demonstrate that bromophenols 2,3,6-tribromo-4,5-dihydroxybenzyl alcohol (1), 2,3,6-tribromo-4,5-dihydroxybenzyl methyl ether (2) and bis-(2,3,6-tribromo-4,5-dihydroxybenzyl) ether (3) from red alga Symphyocladia latiuscula are moderate‒selective human monoamine oxidase-A inhibitors and good dopamine D3/D4 receptor agonists. Bromophenol 3 showed a promising D4R agonist effect with low micromole EC50 value. All of the test ligands were docked against a 3D model of hD3R and hD4R and the result demonstrated strong binding through interaction with prime interacting residues‒Asp110, Cys114, and His349 on hD3R, and Asp115 and Cys119 on hD4R. Overall, the results demonstrated natural bromophenols, especially 1 and 3, from S. latiuscula as multi-target ligands for neuroprotection, especially in PD and schizophrenia.
In Vitro StudyBromophenols from Symphyocladia latiuscula, a red alga, show potential as multi-target ligands for neuroprotection, particularly in Parkinson's disease and schizophrenia.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...